Is Eliquis (apixaban) hepatotoxic and how should liver function be monitored while using it?

Eliquis Hepatotoxicity

Eliquis (apixaban) is not significantly hepatotoxic and does not require routine liver function monitoring in patients with normal or mildly impaired hepatic function. 1

Evidence of Hepatotoxicity

The 2018 European Heart Rhythm Association guidelines explicitly state that no signal for increased hepatotoxicity has been observed in any of the NOAC trials, and the risk of liver injury may even be lower than with warfarin 1. This stands in stark contrast to the withdrawn direct thrombin inhibitor ximelagatran, which was removed from the market in 2006 due to hepatotoxic side effects.

While isolated case reports of apixaban-induced liver injury exist 2, 3, a comprehensive 10-year population-based study from Iceland found zero cases of drug-induced liver injury among 1,903 patients treated with apixaban 4. In this same study, rivaroxaban was the only oral anticoagulant associated with DILI (approximately 1 in 1,100 patients). A 2023 systematic review of 27 DILI cases from DOACs found that rivaroxaban accounted for 74.1% of cases, with apixaban being rarely implicated 5.

Use in Hepatic Impairment

According to the FDA label 6:

• No dose adjustment required for mild hepatic impairment (Child-Pugh A)
• Use with caution in moderate hepatic impairment (Child-Pugh B) - dosing recommendations cannot be provided due to limited clinical experience and potential intrinsic coagulation abnormalities
• Not recommended in severe hepatic impairment (Child-Pugh C)

The 2018 EHRA guidelines reinforce that apixaban may be used with caution in Child-Pugh B cirrhosis, unlike rivaroxaban which should not be used due to >2-fold increase in drug exposure 1. Initiation in Child-Pugh B patients should involve a multidisciplinary team including hepatology and hematology specialists.

Pharmacokinetic studies demonstrate that mild or moderate hepatic impairment has no clinically relevant impact on apixaban exposure or pharmacodynamics, suggesting dose adjustment may not be required 7.

Monitoring Recommendations

Routine liver function monitoring is not indicated for apixaban in patients without pre-existing liver disease. The landmark NOAC trials excluded patients with:

• ALT or AST ≥2-3 times upper limit of normal
• Total bilirubin ≥1.5 times upper limit of normal
• Persistent elevation confirmed by repeated assessment ≥1 week apart 1

When to Check Liver Function:

• Baseline assessment before initiating therapy in patients with known or suspected liver disease
• If clinical symptoms develop: jaundice, malaise, abdominal pain, dark urine (onset typically 40.6 days after starting therapy based on case reports) 5
• Periodic monitoring only in patients with Child-Pugh B cirrhosis who are prescribed apixaban

Clinical Pitfalls

1. Do not confuse apixaban with rivaroxaban - rivaroxaban has significantly higher hepatotoxicity risk and is contraindicated in Child-Pugh B cirrhosis 4, 5

2. Hepatic disease with coagulopathy is an absolute contraindication - all NOACs including apixaban are contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk 1

3. Transaminase elevations during treatment - if ALT/AST rise to ≥2-3x ULN or bilirubin ≥1.5x ULN, discontinue apixaban and investigate alternative causes before considering rechallenge 1